Nonspecific @entity137 of recombinant XXXX activated lymphocytes.

@entity1 @entity137 @entity455 @entity3126 @entity1353 @entity5 @entity843 @entity26 @entity1017 @entity5041 @entity1199 @entity291
The administration of @entity1199 ( @entity1199 ) and lymphokine activated killer (LAK) cells to @entity1 with advanced @entity5 has yielded encouraging results. The purported ability of LAK cells to be discriminatively tumoricidal, thus sparing normal host tissue, represents a major advance over conventional chemotherapy. However, @entity1199 adoptive immunotherapy results in dose-limiting @entity137 characterized by @entity1017 , @entity1353 , @entity843 , and @entity3126 suggestive of a @entity455 . It is unclear whether the observed @entity137 is directly related to @entity1199 and/or LAK cells. The authors examined the cytolytic nature of @entity1 LAK cells against @entity1 endothelial, epithelial, and fibroblast cell lines. @entity291 endothelial cells also were studied. Using a 51Cr release assay, the cytolytic potential, time course, and effect of reactive @entity26 intermediate inhibitors were studied. LAK cells were uniformly toxic against all cell lines, in contrast to high dose @entity5041 and excipient. Significant cytolysis was observed within 30 minutes and increased over the first 2 hours of LAK cells coming in contact with target cells. Reactive @entity26 intermediate inhibitors did not reduce cytolytic activity. The authors thus found @entity1 LAK cells to be rapidly cytolytic against a variety of @entity1 and @entity291 cell lines. This cytolysis was independent of reactive @entity26 intermediates.
